Quarterly Updates7 Aug 2025, 08:32 pm
Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15%; PBT (before exceptional item) at Rs 97 Cr, Up 72%*
AI Summary
Biocon Limited, an innovation-led global biopharmaceuticals company, announced its consolidated financial results for the fiscal first quarter ended June 30, 2025. The company reported an operating revenue of Rs 3,942 crore, up 15% YoY. The EBITDA stood at Rs 829 crore, up 19% on a like-for-like basis. The PBT (before exceptional item) was at Rs 97 crore, up 72%* on a like-for-like basis. The company's generics business delivered a 6% revenue growth, while the biosimilars business reported an 18% YoY growth. Biocon Biologics started FY26 on a strong footing, delivering 18% year-on-year revenue growth. Syngene International reported a revenue growth of 11% YoY.
Key Highlights
- Operating Revenue rose 15% YoY to Rs 3,942 crore
- EBITDA up 19% on a like-for-like basis
- PBT (before exceptional item) at Rs 97 Crore, Up 72%*
- Biosimilars Up 18%, CRDMO Up 11% and Generics Up 6%
- Biocon Biologics reported 18% year-on-year revenue growth